OSU Professor Falsified Data on Eight Papers, Resigns

Ching-Shih Chen’s research involved anticancer therapeutics that were being tested in clinical trials.

Written byCatherine Offord
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

WIKIMEDIA, NHEYOBCancer researcher Ching-Shih Chen of the Ohio State University (OSU) resigned last September after a university investigation found him guilty of scientific misconduct on eight papers, according to a statement released by OSU on Friday (March 30). In a 75-page redacted report also made public on Friday, university investigators conclude that the former professor, whose work centered on the development of anticancer therapeutics, falsified data on at least 14 occasions in the last 12 years.

The investigation into Chen’s work was launched in 2016 after OSU received anonymous allegations of six instances of data falsification in papers published between 2010 and 2014, according to OSU student newspaper, The Lantern. Seizure of Chen’s hard drive led to the discovery of multiple manipulated images, and helped take the number of allegations up to 21.

In eight papers, “Dr. Chen committed Research Misconduct by deviating from the accepted practices of image handling and figure generation and intentionally falsified data,” a three-person committee concluded in the report. In another paper, he was found to have acted “‘recklessly’ by not reviewing or scrutinizing the data provided to him leading to the inappropriate reuse of data.”

C.K. Gunsalus, director of the National Center for Professional and ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • After undergraduate research with spiders at the University of Oxford and graduate research with ants at Princeton University, Catherine left arthropods and academia to become a science journalist. She has worked in various guises at The Scientist since 2016. As Senior Editor, she wrote articles for the online and print publications, and edited the magazine’s Notebook, Careers, and Bio Business sections. She reports on subjects ranging from cellular and molecular biology to research misconduct and science policy. Find more of her work at her website.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies